Vischer Assists LimmaTech Biologics in USD 37 Million Financing
Vischer acted as legal advisor to LimmaTech Biologics as it successfully concluded a USD 37 million (CHF 33 million) Series A financing round, co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.
These funds will empower LimmaTech to progress its proprietary technology platform and expedite the development of preclinical and clinical vaccine candidates targeting increasingly perilous bacterial infections, including shigellosis and gonorrhea. The later stages of clinical development will concentrate on the Shigella vaccine program, developed in collaboration with GSK and recently exclusively licensed by LimmaTech. The company anticipates revealing preliminary results from the ongoing Phase 2 clinical trial of the Shigella program in the latter half of 2023.
The Vischer team includes partner Matthias Staehelin (corporate/M&A, pictured), Nadia Tarolli (partner, tax), Pauline Pfirter (senior associate, corporate/M&A) and Luzius Zumstein (managing associate, corporate/M&A).
Walder Wyss has advised the investors Adjuvant Capital, AXA IM Alts and the Novo Holdings REPAIR Impact Fund in the transaction. The team included partner Alexander Gutmans (pictured below), senior associate Karina Tschon and associates Lucas Maurer as well as Simon Olstein (all corporate/M&A and venture capital).
